Issue 8 · August 13, 2026 · 5 min read
Your whole genome now costs $599
What changes when the test stops being a luxury
A company put a complete genome at $599 this week, and a paper in Cell argued the same afternoon that reading one should be routine medicine. Both are worth a closer look before you act on either.
Aging research has a sex problem: A second Cell paper that landed the same afternoon argues the field has learned less than it could by studying males, and that female reproductive biology holds the overlooked clues. A hypothesis, not a finding.
Your own baseline beats the average: Nature Health followed 1,298 adults for twenty years, measuring thousands of blood proteins along the way. Drifting away from your own protein baseline predicted death better than comparing you with everyone else did.
Approved is not available: Britain's regulator cleared the first GLP-1 in tablet form, Eli Lilly's orforglipron, ahead of both the EU and the US. NHS patients still wait on a separate funding decision nobody has made yet.
A big week for funding: Four longevity rounds closed inside a week, worth roughly $363 million between them. LifeMine's $188 million was the largest, backed by Bezos Expeditions and Gates Frontier, for a drug meant to stop the body rejecting transplanted organs.
The only one with a trial attached: Epicrispr raised $90 million for a therapy that switches a gene off without cutting it, aimed at a rare muscle disease. Its first trial has finished enrolling, with data due later this year.
Immune memory, rewritten: Infinimmune raised $75 million, co-led by Regeneron Ventures, to re-engineer how the immune system remembers. Skin aging is the stated destination; the candidates going to the clinic first are for eczema.
Fat cells as factories: Eli Lilly joined the first close of Remedium's $10 million round, behind a platform designed to turn fat cells into long-term, adjustable producers of therapeutic proteins.
Twenty advance, ten get paid: XPRIZE Healthspan named the finalists for the clinical phase of its $101 million competition, and those are two different numbers. Trials run to 2029 in adults aged 50 to 90.
A faster queue, not a result: The FDA fast-tracked HAYA's approach to reversing scarring in the heart rather than managing it. Fast track speeds the review and says nothing about whether the treatment works.
The trust market is getting crowded: David Sinclair launched Lifespan.com, a science-media platform pitched on separating evidence from opinion. It drew more views than anything else we saw this week, and it is a launch rather than a result.
Dogs first: GenFlow reported early results from its aging-dog program. Companion animals matter here mostly for what they do to human timelines, and these results are early.
Menopause care goes long-term: Winona launched a supplement framed as a move from relieving symptoms to protecting long-term health. A product launch and a marketing frame, with no evidence claim attached.
Old calculators, new data: Longevity AI and Meir Medical Center are testing whether decades-old clinical risk tools predict better when fed real patient records. A collaboration so far, with nothing to report.
Featured
A $599 whole genome, and a paper arguing it should be routine
Cell published the paper last Thursday afternoon: a vision piece from David Sinclair and colleagues, arguing that reading complete genomes — telomere to telomere, with AI assistance — should become part of standard preventive care. Ninety-nine minutes later, Human Longevity announced clinical-grade whole-genome sequencing at $599.
The paper argues, it does not show. A vision for where the field should go, not a result.
The price is the seller's own. Another outlet published $600 for the same launch.
Clinical-grade is the company's word. Nobody outside it has checked what the test returns.
The question changes. Not whether you can afford it, but what you would do with the answer.
The argument for reading everyone's genome is loudest from people with something to sell. The price falling anyway is what turns a pitch into a real question.
If you are weighing one, ask what the report returns and who reads it with you. A clinician who knows your history turns data into a decision.
More this week
Thirty years without dementia, or seventeen
Researchers followed 12,409 American adults from their mid-fifties into their nineties, checking three things in midlife: diabetes, high blood pressure, and smoking.
People who had none of the three went on to live about thirty years free of dementia after 55. People who had all three managed about seventeen and a half.
The gap is not that the high-risk group got more dementia. By their nineties they had less of it, because many more of them had already died. What they lost was the years.
The peptide clinics won the vote. Now comes the bill.
A former FDA official published the first serious read on what the compounded-peptide votes change and what they leave exactly where it was.
The advisory committee sided with the clinics. But a committee recommends and does not write rules, and the analysis is blunt about who is holding the risk if a patient is harmed.
The vote itself is a couple of weeks old. What is new is the accounting of what it actually bought.
Two people who study aging cannot agree how close it is
National Geographic asked whether we are on the brink of ending aging. A working biogerontologist answered in public that we are not.
His case: the strongest life-extending intervention ever demonstrated in mice is still eating less, and it was found almost a century ago.
We are not refereeing it. It is worth your attention because the people who do this for a living disagree about how close the field is, and that disagreement tells you more than either headline on its own.
On the radar
CMS proposed a fast lane for Medicare to cover breakthrough devices, aimed at a wait that can currently run years. It is a notice open for comment until 13 October, not a rule. Watch whether it comes out the other side intact.
Go deeper at longevity.io